Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8,705 Mln
P/E Ratio
22.77
P/B Ratio
14.46
Industry P/E
--
Debt to Equity
0
ROE
0.66 %
ROCE
--
Div. Yield
0 %
Book Value
19.94
EPS
13.13
CFO
$2,050.46 Mln
EBITDA
$1,684.51 Mln
Net Profit
$1,057.34 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Medpace Holdings (MEDP)
| -10.14 | -9.69 | -13.23 | -24.90 | 25.62 | 28.92 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Medpace Holdings (MEDP)
| 8.31 | 44.31 | -2.40 | 56.35 | 65.60 | 58.81 | 45.67 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.91 | 62.04 | -- | -155.16 | |
| 2.68 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 24.99 | 2,881.32 | -- | -14.59 |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in... various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio. Read more
Chairman & CEO
Dr. August James Troendle M.D.
Chairman & CEO
Dr. August James Troendle M.D.
Headquarters
Cincinnati, OH
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Medpace Holdings Inc (MEDP) stood at $ 3,020 Mln as on 31-Mar-25
The share price of Medpace Holdings Inc (MEDP) is $298.55 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Medpace Holdings Inc (MEDP) has given a return of 25.62% in the last 3 years.
Medpace Holdings Inc (MEDP) has a market capitalisation of $ 8,705 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Medpace Holdings Inc (MEDP) is 14.46 times as on 25-Apr-2025, a 554% premium to its peers’ median range of 2.21 times.
The P/E ratio of Medpace Holdings Inc (MEDP) is 22.77 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Medpace Holdings Inc (MEDP) and enter the required number of quantities and click on buy to purchase the shares of Medpace Holdings Inc (MEDP).
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
The CEO & director of Dr. August James Troendle M.D.. is Medpace Holdings Inc (MEDP), and CFO & Sr. VP is Dr. August James Troendle M.D..
There is no promoter pledging in Medpace Holdings Inc (MEDP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
290
|
|
|
80
|
|
|
8
|
|
|
6
|
| Medpace Holdings Inc. (MEDP) | Ratios |
|---|---|
|
Return on equity(%)
|
66.44
|
|
Operating margin(%)
|
10.38
|
|
Net Margin(%)
|
19.31
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Medpace Holdings Inc (MEDP) was $0 Mln.
$-4.33
(
